Helmut R Maecke Selected Research

DOTA-Tyr(3)- 90Y-octreotide

1/2017	Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.
2/2015	Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.
1/2006	Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
8/2005	Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Helmut R Maecke Research Topics

Disease

59	Neoplasms (Cancer) 07/2020 - 02/2002
16	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2018 - 05/2002
8	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 10/2003
3	Insulinoma 07/2020 - 01/2016
2	Diabetes Mellitus 01/2017 - 01/2017
2	Brain Neoplasms (Brain Tumor) 01/2017 - 12/2011
2	Meningioma (Meningiomas) 10/2016 - 02/2015
2	Breast Neoplasms (Breast Cancer) 01/2016 - 12/2011
2	Glioblastoma (Glioblastoma Multiforme) 12/2011 - 06/2006
2	Glioma (Gliomas) 12/2011 - 06/2006
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2011 - 12/2011
2	Carcinoma (Carcinomatosis) 02/2011 - 07/2005
2	Neoplasm Metastasis (Metastasis) 01/2008 - 10/2003
1	Congenital Hyperinsulinism 07/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2016
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2016
1	Lymphoma (Lymphomas) 01/2016
1	Gastrinoma 01/2015
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2014
1	Necrosis 11/2014
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2013
1	Ovarian Neoplasms (Ovarian Cancer) 12/2011
1	medullary Thyroid cancer 04/2011
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2009
1	Thyroid Neoplasms (Thyroid Cancer) 05/2009

Drug/Important Bio-Agent (IBA)

21	Somatostatin Receptors (Somatostatin Receptor)IBA 10/2016 - 02/2002
18	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018 - 02/2002
18	Peptides (Polypeptides)IBA 01/2018 - 01/2004
14	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 07/2020 - 01/2005
14	Bombesin Receptors (Bombesin Receptor)IBA 01/2019 - 09/2004
12	BombesinIBA 08/2015 - 09/2004
11	Radioisotopes (Radionuclides)IBA 06/2015 - 02/2002
9	Peptide Receptors (Peptide Receptor)IBA 06/2015 - 04/2007
7	AcidsIBA 06/2009 - 09/2004
6	LigandsIBA 01/2016 - 04/2008
6	Octreotide (Sandostatin)FDA LinkGeneric 10/2010 - 01/2005
5	Edotreotide (SMT 487)IBA 03/2017 - 02/2002
4	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2017 - 08/2009
4	DOTA-Tyr(3)- 90Y-octreotideIBA 01/2017 - 08/2005
4	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acidIBA 05/2009 - 01/2005
4	3-Tyr-octreotideIBA 05/2009 - 01/2005
3	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 01/2018 - 01/2015
3	Cholecystokinin B ReceptorIBA 06/2015 - 04/2011
3	edotreotide lutetium LU-177IBA 02/2015 - 08/2005
3	IntegrinsIBA 11/2014 - 08/2011
3	GastrinsIBA 12/2011 - 11/2008
2	somatostatin receptor 2IBA 03/2017 - 03/2012
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2017 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2016
2	Immunoconjugates (Immunoconjugate)IBA 01/2016 - 07/2005
2	DOTA(0)-Tyr(3)- 177Lu-octreotideIBA 02/2015 - 08/2005
2	Aspartic Acid (Aspartate)FDA Link 11/2014 - 12/2011
2	Arginine (L-Arginine)FDA Link 11/2014 - 12/2011
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2014 - 12/2011
2	Substance PIBA 12/2011 - 06/2006
2	DOTA-PEG(4)-bombesin (7-14)IBA 02/2011 - 08/2007
2	Ga(III)-DOTATOCIBA 01/2011 - 02/2002
2	Biological ProductsIBA 06/2006 - 12/2005
2	Pentetic Acid (DTPA)FDA LinkGeneric 01/2005 - 09/2004
1	Glucagon-Like Peptide-1 ReceptorIBA 07/2020
1	Exenatide (Byetta)FDA Link 07/2020
1	AntigensIBA 01/2017
1	Urea (Carbamide)FDA LinkGeneric 01/2017
1	Brentuximab VedotinIBA 01/2016
1	Progesterone FDA LinkGeneric 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Copper-64IBA 08/2015
1	alanyltyrosineIBA 08/2015
1	minigastrinIBA 06/2015
1	EstersIBA 01/2015
1	Bevacizumab (Avastin)FDA Link 11/2014
1	Angiogenesis InhibitorsIBA 11/2014
1	GelatinIBA 06/2014
1	Serine Proteases (Serine Protease)IBA 06/2014
1	IncretinsIBA 06/2014
1	gastric inhibitory polypeptide receptorIBA 06/2014
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 06/2014
1	glycylhistidineIBA 01/2014
1	n-hexadecaneIBA 01/2014
1	Rituximab (Mabthera)FDA Link 07/2013
1	Folic Acid (Vitamin M)FDA LinkGeneric 05/2012
1	A-factor (Streptomyces)IBA 05/2012
1	Pemetrexed (MTA)FDA Link 05/2012
1	Folic Acid AntagonistsIBA 05/2012
1	aspartic acid glycine arginineIBA 08/2011
1	Glutamic Acid (Glutamate)FDA Link 04/2011
1	AndrogensIBA 02/2011
1	pasireotideIBA 10/2010
1	AntibodiesIBA 09/2009
1	Thyroglobulin FDA Link 05/2009
1	YttriumIBA 05/2009
1	IodineIBA 05/2009
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2008
1	Neuropeptide YIBA 11/2008

Therapy/Procedure

27	Therapeutics 07/2020 - 02/2002
14	Radiotherapy 01/2014 - 02/2002
3	Aftercare (After-Treatment) 01/2017 - 08/2005
2	Radioimmunotherapy 07/2013 - 07/2005
1	Catheters 12/2011
1	Intravenous Injections 06/2009